PPARD and cardiac hypertrophy: Cardiomyocyte-specific deletion of PPARδ (CM-PPARδ) results in a downregulation of key FAO genes that limits the myocardial lipid-consumption rate, leading to triacylglyceride accumulation, cardiac hypertrophy, congestive HF, and reduced survival [44].